Genmab A/S 股票的价格表现如何？

Genmab A/S 的当前价格为 $31.4，在上个交易日上升了 0.22%。

Genmab A/S 的主要业务主题或行业是什么？

Genmab A/S 属于 Biotechnology 行业，该板块是 Health Care

Genmab A/S 的市值是多少？

Genmab A/S 的当前市值是 $19.3B

Genmab A/S 是买入、卖出还是持有？

据华尔街分析师称，共有 17 位分析师对 Genmab A/S 进行了分析师评级，包括 4 位强烈买入，14 位买入，6 位持有，1 位卖出，以及 4 位强烈卖出

Genmab A/S（GMAB）股价、图表、新闻与AI分析

Q: Genmab A/S 股票的价格表现如何？

Genmab A/S 的当前价格为 $31.4，在上个交易日 上升 了 0.22%。

主页

股票

GMAB

GMAB 价格

Genmab A/S

$31.33

-2.85%

$-0.92

收盘价：Jan 20, 16:00:00 GMT-5

$31.4

0.22%

$0.07

盘后：Jan 20, 20:00:00 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$32.25

开盘价

$31.38

当日区间

$31.05 - $31.68

52周范围

$17.23 - $35.43

交易量

2.7M

平均成交量

1.8M

每股收益（TTM）

2.29

股息收益率

市值

$19.3B

什么是 Genmab A/S？

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

功能特性

交易策略